In the Russian Federation, there is an unmet need for research of non-radiographic (nr) axial spondyloarthritis (nr-axSpA). Therefore, the noninterventional multicenter NiSpAR study was initiated in 2022. Objective: to describe a cohort of patients with nr-axSpA and approaches to its diagnosis in the Russian Federation. Material and methods . The study involved 20 research centers from different regions of the Russian Federation. The article presents the results of prospective follow-up. Of 272 screened patients with a preliminary diagnosis of nr-axSpA, 113 (41.5%) met the 2009 ASAS criteria. The mean age of the patients was 37.1±11.2 years, and the median disease duration was 17 [5; 60] months. The proportion of participants with a diagnosis duration of <2 years was 54.6%. More than half of the patients were male (52.2%). HLA-B27 positivity was detected in 70.8% of cases. The mean BASDAI and ASDAS-CRP scores were 3.6±2.0 and 2.7±0.9, respectively. Before inclusion in the study, the vast majority of patients received nonsteroidal anti-inflammatory drugs (94.7%), predominantly coxibs (55.5%); the synthetic disease-modifying antirheumatic drugs (DMARDs) sulfasalazine and methotrexate were used in 20.4 and 9.7%, respectively, systemic glucocorticoids in 3.5%, and biologic diseasemodifying antirheumatic drugs (bDMARDs) 9.7%. Results and discussion . Objective signs of inflammation were present in 85 (75.2%) patients; active sacroiliitis was detected by magnetic resonance imaging in 77 (68.1%), and elevated serum CRP levels were found in 40 (35.4%). During the 104 weeks of the study, a significant decrease in nr-axSpA activity according to the ASDAS and BASDAI indices was observed. Positive changes in CRP levels were noted, with the median decreasing 2.5-fold compared with baseline. The number of patients with very high nr-axSpA activity decreased almost 7-fold and that of patients with high activity decreased 1.7-fold; correspondingly, the proportion of patients with inactive disease increased, reaching a maximum of 60% at visit 3. The size of the group with low disease activity remained virtually unchanged by the end of follow-up. At the end of follow-up, radiographic axSpA/ankylosing spondylitis was diagnosed in 12 (10.6%) participants. The number of patients receiving bDMARDs increased to 14 (12.3%) by the end of the study. At baseline, physicians considered that 64.6% of patients required bDMARDs; this proportion was 20–30% by visit 2 and at subsequent visits. Conclusion . The results of the prospective stage of the study showed that, in real-world clinical practice, there is a continuing positive trend toward improved diagnosis of nr-axSpA, including its early forms with a duration of axial symptoms of up to 2 years. Treatment tactics are consistent with international standards. At the same time, there are limitations in prescribing bDMARDs and targeted synthetic DMARDs (tsDMARDs) to all patients who require them, which necessitates improved access to treatment in order to reduce the medical, social, and economic burden of axSpA in Russia.